[Dual bronchodilators becomes the first choice combination].
.
Dirk
D
Einecke
D058666:Adrenergic beta-2 Receptor Agonists / Q000627:therapeutic use; D004311:Double-Blind Method; D004338:Drug Combinations; D000068298:Fluticasone / Q000627:therapeutic use; D006024:Glycopyrrolate / Q000627:therapeutic use*; D019983:Guideline Adherence; D006801:Humans; D007189:Indans / Q000627:therapeutic use*; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D015363:Quinolones / Q000627:therapeutic use*; D000068299:Salmeterol Xinafoate / Q000627:therapeutic use
D058666:Adrenergic beta-2 Receptor Agonists; D004338:Drug Combinations; D007189:Indans; D018727:Muscarinic Antagonists; D015363:Quinolones; D000068299:Salmeterol Xinafoate; C510790:indacaterol; D000068298:Fluticasone; D006024:Glycopyrrolate